CL2012002296A1 - Polypeptide because it comprises a tenth domain of fibronectin type III and that binds to interleukin 23 (il-23); pharmaceutical composition comprising said polypeptide; A method for regulating the pathogenicity of th17 lymphocytes which comprises contacting the aforementioned polypeptide with il-23. - Google Patents

Polypeptide because it comprises a tenth domain of fibronectin type III and that binds to interleukin 23 (il-23); pharmaceutical composition comprising said polypeptide; A method for regulating the pathogenicity of th17 lymphocytes which comprises contacting the aforementioned polypeptide with il-23.

Info

Publication number
CL2012002296A1
CL2012002296A1 CL2012002296A CL2012002296A CL2012002296A1 CL 2012002296 A1 CL2012002296 A1 CL 2012002296A1 CL 2012002296 A CL2012002296 A CL 2012002296A CL 2012002296 A CL2012002296 A CL 2012002296A CL 2012002296 A1 CL2012002296 A1 CL 2012002296A1
Authority
CL
Chile
Prior art keywords
polypeptide
pathogenicity
interleukin
lymphocytes
binds
Prior art date
Application number
CL2012002296A
Other languages
Spanish (es)
Inventor
Alex Bush
Ruchira Dasgupta
Linda Engle
Lumelle Schneeweis
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2012002296A1 publication Critical patent/CL2012002296A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)

Abstract

Polipéptido porque comprende un dominio decimo de fibronectina de tipo III y que se une a interleucina 23 (IL-23); composición farmacéutica que comprende dicho polipéptido; procedimiento para regular la patogenicidad de los linfocitos th17 que comprende poner en contacto el polipéptido antes mencionado con IL-23.Polypeptide because it comprises a tenth domain of type III fibronectin and that binds to interleukin 23 (IL-23); pharmaceutical composition comprising said polypeptide; method for regulating the pathogenicity of th17 lymphocytes comprising contacting the aforementioned polypeptide with IL-23.

CL2012002296A 2010-02-18 2012-08-17 Polypeptide because it comprises a tenth domain of fibronectin type III and that binds to interleukin 23 (il-23); pharmaceutical composition comprising said polypeptide; A method for regulating the pathogenicity of th17 lymphocytes which comprises contacting the aforementioned polypeptide with il-23. CL2012002296A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30556610P 2010-02-18 2010-02-18
US33070610P 2010-05-03 2010-05-03

Publications (1)

Publication Number Publication Date
CL2012002296A1 true CL2012002296A1 (en) 2013-01-11

Family

ID=43901183

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002296A CL2012002296A1 (en) 2010-02-18 2012-08-17 Polypeptide because it comprises a tenth domain of fibronectin type III and that binds to interleukin 23 (il-23); pharmaceutical composition comprising said polypeptide; A method for regulating the pathogenicity of th17 lymphocytes which comprises contacting the aforementioned polypeptide with il-23.

Country Status (19)

Country Link
US (2) US8927693B2 (en)
EP (1) EP2536757B1 (en)
JP (1) JP2013520426A (en)
KR (1) KR20130010461A (en)
CN (1) CN102762591A (en)
AR (1) AR080229A1 (en)
AU (1) AU2011218243A1 (en)
BR (1) BR112012019881A2 (en)
CA (1) CA2790329A1 (en)
CL (1) CL2012002296A1 (en)
EA (1) EA201270713A1 (en)
HK (1) HK1179276A1 (en)
MX (1) MX2012009050A (en)
PE (1) PE20130041A1 (en)
SG (1) SG183215A1 (en)
TN (1) TN2012000372A1 (en)
TW (1) TWI508736B (en)
WO (1) WO2011103105A1 (en)
ZA (1) ZA201206969B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
JP5537946B2 (en) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Targeted therapeutic agents based on modified proteins for tyrosine kinase receptors including IGF-IR
CN102007145A (en) 2008-02-14 2011-04-06 百时美施贵宝公司 Targeted therapeutics based on engineered proteins that bind egfr
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Human il-23 antigen binding proteins
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP6023703B2 (en) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Fibronectin based scaffold proteins with improved stability
AP3953A (en) 2010-11-04 2016-12-22 Boehringer Ingelheim Int Anti-IL-23 antibodies
US9260496B2 (en) 2010-12-22 2016-02-16 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
LT2697257T (en) 2011-04-13 2016-12-27 Bristol-Myers Squibb Company Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
WO2012158739A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US20140302999A1 (en) * 2011-11-03 2014-10-09 Magdalena Leszczyniecka Method for determination of pharmacological properties of recombinant proteins
CN109206516A (en) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 Anti-il-23 p 19 antibodies
TWI694085B (en) 2012-09-13 2020-05-21 美商必治妥美雅史谷比公司 Fibronectin based scaffold domain proteins that bind to myostatin
CZ2012829A3 (en) 2012-11-23 2014-06-11 Biotechnologický Ústav Av Čr, V.V.I. Polypeptides for the treatment of autoimmune diseases based on blocking a receptor for human IL-23 cytokine
WO2014120891A2 (en) * 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014124017A1 (en) * 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
WO2014126884A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company High ph protein refolding methods
KR20150062352A (en) * 2013-11-29 2015-06-08 일진엘이디(주) Light emitting diode having dielectric layer
EP3129401B1 (en) 2014-03-20 2019-06-12 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
MX2017002765A (en) 2014-09-03 2017-10-16 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof.
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
EP3733698A1 (en) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3 binding fibronectin based scafflold molecules
JP6872797B2 (en) * 2015-12-29 2021-05-19 国立大学法人東京工業大学 Method for stabilizing target-binding peptide
TW201842929A (en) * 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JP3095175B2 (en) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
PT971946E (en) 1997-01-21 2006-11-30 Gen Hospital Corp Selection of proteins using rna-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
ES2564161T3 (en) 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Artificial antibody polypeptides
EP2141243A3 (en) * 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
PT2316852E (en) 2002-11-08 2014-06-23 Ablynx Nv Stabilized single domain antibodies
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
SI1729795T1 (en) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
CN1317389C (en) * 2004-09-02 2007-05-23 中国人民解放军军事医学科学院放射与辐射医学研究所 Structure of antisense digonucleotide for inhibiting fibronectin expression and use
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
DE102006032337A1 (en) 2006-07-12 2008-01-17 BSH Bosch und Siemens Hausgeräte GmbH Method for controlling a spin cycle of a washing machine and suitable for performing the method suitable washing machine
JP5537946B2 (en) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Targeted therapeutic agents based on modified proteins for tyrosine kinase receptors including IGF-IR
PT2059534E (en) * 2007-02-23 2012-07-17 Schering Corp Engineered anti-il-23p19 antibodies
EP2417974A1 (en) * 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
EP2641919A3 (en) 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
EP2234646A2 (en) * 2007-12-27 2010-10-06 Novartis AG Improved fibronectin-based binding molecules and their use
CN102007145A (en) * 2008-02-14 2011-04-06 百时美施贵宝公司 Targeted therapeutics based on engineered proteins that bind egfr
PL2439212T3 (en) * 2008-05-02 2017-06-30 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
AU2010230311B9 (en) 2009-04-27 2012-09-20 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit

Also Published As

Publication number Publication date
PE20130041A1 (en) 2013-01-28
EP2536757A1 (en) 2012-12-26
ZA201206969B (en) 2015-06-24
HK1179276A1 (en) 2013-09-27
TWI508736B (en) 2015-11-21
US20150274806A1 (en) 2015-10-01
KR20130010461A (en) 2013-01-28
US20130012436A1 (en) 2013-01-10
EA201270713A1 (en) 2013-01-30
EP2536757B1 (en) 2015-03-25
TN2012000372A1 (en) 2014-01-30
US9714281B2 (en) 2017-07-25
AU2011218243A1 (en) 2012-10-04
MX2012009050A (en) 2012-09-07
WO2011103105A1 (en) 2011-08-25
CN102762591A (en) 2012-10-31
AR080229A1 (en) 2012-03-21
JP2013520426A (en) 2013-06-06
CA2790329A1 (en) 2011-08-25
SG183215A1 (en) 2012-09-27
BR112012019881A2 (en) 2017-06-27
TW201130501A (en) 2011-09-16
US8927693B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
CL2012002296A1 (en) Polypeptide because it comprises a tenth domain of fibronectin type III and that binds to interleukin 23 (il-23); pharmaceutical composition comprising said polypeptide; A method for regulating the pathogenicity of th17 lymphocytes which comprises contacting the aforementioned polypeptide with il-23.
CL2012002884A1 (en) Polypeptide comprising a tenth domain of type III fibronectin that binds to the covertase subtilisin kexin type q protein (pcsk9); pharmaceutical composition comprising said polypeptide.
ECSP12012317A (en) USEFUL PREDICTIVE MARKERS IN THE TREATMENT OF FRAGILE SYNDROME X (FXS)
CY1119041T1 (en) ALCOHOLIC COMPOSITIONS PRESENTING REDUCED RISK OF EDUCATION
CO7111287A2 (en) Pesticide compositions and related processes
CL2012002125A1 (en) Method for purification of antibodies from a protein mixture in a bioreactor; operational unit that is used in the method described above.
CO6741156A2 (en) Pesticide compositions and related processes
CO6741157A2 (en) Pesticide compositions and processes related to said compositions
UY34177A (en) NEW INHIBITING COMPOUNDS OF PHOSPHODESTERASE TYPE 10A
CO6450665A2 (en) ANTI-FGFR3 ANTIBODIES AND METHODS THAT USE THEM
UA114611C2 (en) PESTICIDIC COMPOSITIONS AND METHODS RELATING TO THEM
AR069474A1 (en) ANTI-CORROSIVE MATERIAL
UY33958A (en) GLUCOSILCERAMIDE SINTASA INHIBITORS
UY34365A (en) HETEROCICLICAL COMPOUNDS
CL2009000650A1 (en) Compounds derived from amino-pyrazine, kinase-pi 3 inhibitors; pharmaceutical composition; and use for the treatment of inflammatory or allergic conditions, such as respiratory diseases, rheumatoid arthritis, ulcerative colitis, among others.
BR112014001834A2 (en) nematode biocontrol
CR20120463A (en) OIL FORMULATIONS THAT INCLUDE CYCLOPROPEN COMPOUNDS
BR112014011254A2 (en) 2-thiopyrimidinones
AR082422A1 (en) LIQUID DETERGENT COMPOSITION
UY34800A (en) PHARMACEUTICAL COMBINATIONS CONTAINING AN INHIBITOR OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE-1 USEFUL IN METABOLIC DISORDERS
BR112015009301A2 (en) nematode biocontrol
UY33856A (en) ? GEN AND VARIATIONS ASSOCIATED WITH THE BM1 PHENOTYPE, MOLECULAR MARKERS AND ITS USE ?.
CY1119468T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RISK
EA201300733A1 (en) RECOMBINANT MICOBACTERIA AS A VACCINE
BR112013000840A2 (en) method for enhancing the effect of potentiated activated form of antibody to biological endogenous molecule, pharmaceutical composition and use of combination of endogenous biological molecule with potentiated activated form of antibody to endothelial synthase.